, a clinical stage biopharmaceutical company, focuses on the discovery
, research, and development of biologic drugs and oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for the treatment of anemia in chronic kidney disease patients. The company’s lead drug candidate is XBIO-101, a small-molecule interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market drug candidates. Xenetic Biosciences
is headquartered in Lexington, Massachusetts.
If you followed the long signal last month you are very happy today. We do not anticipate a big dip after today although you could wait to see some consolidation at this new all time high.